Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated With Preoperative Chemoradiation Therapy for Rectal Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 775-781

  Park, Hee Chul ^a   Janjan, Nora A ^a   Mendoza, Tito R ^a   Lin, Edward H ^a   Vadhan Raj, Saroj ^a   Hundal, Mandeep ^a   Zhang, Yiqun ^a   Delclos, Marc E ^a   Crane, Christopher H ^a   Das, Prajnan ^a   Wang, Xin Shelley ^a   Cleeland, Charles S ^a   Krishnan, Sunil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Down staging; Fatigue; Neoadjuvant chemoradiation; Rectal cancer; Tumor response

Indexed keywords

DOWN-STAGING; FATIGUE; NEOADJUVANT CHEMORADIATION; RECTAL CANCER; TUMOR RESPONSE;

FLUORESCENT SCREENS; PARAMAGNETIC RESONANCE; PATIENT MONITORING; TELEVISION PICTURE TUBES;

TUMORS;

CAPECITABINE;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DROWSINESS; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM CANCER; SCORING SYSTEM;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PAIN; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REMISSION INDUCTION; SLEEP STAGES; YOUNG ADULT;

EID: 70349558339     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.027     Document Type: Article

References (49)

1. Fallowfield L. Quality of life: A new perspective for cancer patients. Nat Rev Cancer 2 (2002) 873-879
2. Paice J.A. Assessment of symptom clusters in people with cancer. J Natl Cancer Inst Monogr (2004) 98-102
3. Mendoza T.R., Wang X.S., Cleeland C.S., et al. The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85 (1999) 1186-1196
4. Cleeland C.S., Mendoza T.R., Wang X.S., et al. Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 89 (2000) 1634-1646
5. Wang X.S., Fairclough D.L., Liao Z., et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24 (2006) 4485-4491
6. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 21 (2003) 3502-3511
7. Geels P., Eisenhauer E., Bezjak A., et al. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18 (2000) 2395-2405
8. Langendijk J.A., Aaronson N.K., de Jong J.M., et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 19 (2001) 2123-2133
9. Modi S., Panageas K.S., Duck E.T., et al. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20 (2002) 3665-3673
10. Eton D.T., Fairclough D.L., Cella D., et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21 (2003) 1536-1543
11. Earlam S., Glover C., Fordy C., et al. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14 (1996) 171-175
12. Maisey N.R., Norman A., Watson M., et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38 (2002) 1351-1357
13. Roychowdhury D.F., Hayden A., and Liepa A.M. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21 (2003) 673-678
14. Fang F.M., Tsai W.L., Chiu H.C., et al. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 1394-1404
15. Efficace F., Bottomley A., Coens C., et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?. Eur J Cancer 42 (2006) 42-49
16. McCarter H., Furlong W., Whitton A.C., et al. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. J Clin Oncol 24 (2006) 3636-3643
17. Groenvold M., Petersen M.A., Idler E., et al. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat 105 (2007) 209-219
18. Krishnan S., Janjan N.A., Skibber J.M., et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) 762-771
19. Efficace F., and Bottomley A. Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer. J Clin Oncol 23 (2005) 1335-1336 author reply 1336
20. Rodgers III G.M., Cella D., Chanan-Khan A., et al. Cancer- and treatment-related anemia. J Natl Compr Canc Netw 3 (2005) 772-789
21. Mock V., Atkinson A., Barsevick A., et al. NCCN practice guidelines for cancer-related fatigue. Oncology 14 (2000) 151-161
22. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
23. Krishnan S., Rana V., Janjan N.A., et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107 (2006) 2589-2596
24. Lee W.R., Berkey B., Marcial V., et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42 (1998) 1069-1075
25. Dubray B., Mosseri V., Brunin F., et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 201 (1996) 553-558
26. Prosnitz R.G., Yao B., Farrell C.L., et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1087-1095
27. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
28. Laurie S.A., Ding K., Whitehead M., et al. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: A combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 18 (2007) 1051-1055
29. Henke M., Sindlinger F., Ikenberg H., et al. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol 180 (2004) 45-51
30. Fyles A.W., Milosevic M., Pintilie M., et al. Anemia, hypoxia and transfusion in patients with cervix cancer: A review. Radiother Oncol 57 (2000) 13-19
31. Rades D., Lang S., Schild S.E., et al. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol (R Coll Radiol) 18 (2006) 139-144
32. Varlotto J., and Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63 (2005) 25-36
33. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23 (2005) 5960-5972
34. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
35. Thomas G., Ali S., Hoebers F.J., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108 (2008) 317-325
36. Hedenus M., Adriansson M., San Miguel J., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
37. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
38. Bennett C.L., Silver S.M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
39. Geinitz H., Zimmermann F.B., Stoll P., et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 51 (2001) 691-698
40. Bower J.E., Ganz P.A., Aziz N., et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64 (2002) 604-611
41. Wratten C., Kilmurray J., Nash S., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59 (2004) 160-167
42. Meyerhardt J.A., Sloan J.A., Sargent D.J., et al. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1402-1410
43. Meyers C.A., Albitar M., and Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104 (2005) 788-793
44. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005) 1757-1764
45. Schubert C., Hong S., Natarajan L., et al. The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain Behav Immun 21 (2007) 413-427
46. Karin M., and Greten F.R. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
47. Mukogawa T., Koyama F., Tachibana M., et al. Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 94 (2003) 745-750
48. Voboril R., and Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: Impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 53 (2006) 518-523
49. Voboril R., and Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma 54 (2007) 495-502